Jacobs Journal of Experimental Cardiology and research

Effectiveness of Autologous Bone Marrow-Derived Mononuclear Cells Delivery in Wide Spectrum of Pathologies

*Aris Lacis
Department Of Cardiology, University Children Hospital, Latvia

*Corresponding Author:
Aris Lacis
Department Of Cardiology, University Children Hospital, Latvia

Published on: 2019-06-28


The promising field of regenerative medicine is working to restore structure and function of damaged tissues and organs. The adult heart represents an attractive candidate for cell-based technologies. While there is a wealth of preclinical and clinical data showing the safety, feasibility, and efficacy of stem cells in adults with acute myocardial infarction and heart failure, less is known about possible implementation of stem cell therapy in infants and children with heart failure due to dilated cardiomyopathy and pulmonary arterial hypertension. The challenges facing cardiac stem cell therapy are multiple. There are uncertainties around the destiny of stem cells after their injection into the blood stream. In particular, it regards migration and homing of implanted cells in the target tissues. As yet unclear is the possible role of sympathetic nervous system in the context of osteoreflexotherapy. There is still no definitive answer to the question on which is the preferred type of stem cells to be used for transplantation in different settings. Since 2008, at first we used autologous bone marrow-derived mononuclear cells (BM-MNCs) in patient with acute myocardial infarction. We have investigated the use of stem cells not only for myocardial regeneration, but also in patients with diabetes mellitus and osteoarthritis in adult patients. Since 2009, we started stem cells implantation for pediatric patients


Effectiveness, Autologous Bone Marrow


To determine the role of BM-MNCs in management of wide spectrum of pathologies, including critically ill pediatric patients suffering from idiopathic dilated cardiomyopathy and severe pulmonary arterial hypertension and adult patients with acute myocardial infarction and heart failure and adult patients with osteoarthritis of splenic artery or superior pancreatic duodenal artery we have performed single intra-articular BM-MNCs injections in 70 patients with knee or hip joint osteoarthritis (stage II– III). No adverse effects after the BM-MNC injection were observed. Preliminary analysis showed decrease in pain and other symptoms and statistically significant improvement by clinical scoring system using different questionnaires.